Vitura Health Limited · ASX:VIT
Vitura Health — H1 FY2025 Earnings Presentation
26 slides from Vitura Health's earnings presentation, Feb 28, 2025
Slide 1: H1 FY2025 financial results Investor webinar and presentation
ASX ANNOUNCEMENT H1 FY2025 financial results Investor webinar and presentation 28 FEBRUARY 2025 Melbourne, Australia – Vitura Health Limited (ASX: VIT) (Vitura and Company), a leading digital health business, is pleased to confirm details of the investor webinar that will be held later today at whic
Slide 2: About Vitura Health Limited
About Vitura Health Limited (ASX: VIT) www.vitura.com.au Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses: www.burleighheadscannabis.com Burleigh Heads Cannabis operates the market le
Slide 3: Forward-looking statements
Authorised by Robert Iervasi, Chair and Non-Executive Director Contact Vitura Health Limited Media enquiries Robert Iervasi Dieter Lehmann Chair Nominis Communications 1300 799 491 +61 427 672 995 info@vitura.com.au dieter@nominis.me For personal use only Forward-looking statements This announcement
Slide 4: Commercial in Confidence
For personal use only COMMERCIAL IN CONFIDENCE
Slide 5: Agenda
For personal use only AGENDA • Company Overview • H1 FY2025 Highlights and Leadership • Operational Overview • Detailed Financials • Outlook
Slide 6: Company Overview
For personal use only Vitura is a leading digital health business focused on innovative healthcare delivery through a centralised platform called Canview. Company Information (as 26 February 2025) Shares on issue 662,254,856 Our operations are divided into three segments allowing us to be involved i
Slide 7: H1 FY2025 Highlights
H1 FY2025 HIGHLIGHTS For personal use onl il
Slide 8: Board and Executive Team
For personal use only Board Executive Team Geoffrey Cockerill, Chief Executive Officer Daniel Birch, Independent Non-Executive Director • Commenced 25 November 2024 • Appointed 27 November 2024 Gerard Fogarty AO, Independent Non-Executive Director Nicola Swarbrick, Chief Operating Officer • Appointe
Slide 9: Strategic priorities
For personal use only • Maintain market leadership • Increase customer • Enhance and expand • Disciplined approach to in medicinal cannabis and retention and acquisition Doctors On Demand and costs and a commitment nicotine vaping products. through expansion of Canview platforms to to growing multip
Slide 10: Revenue growth in H1 FY2025 of 4.5%
For personal use only REVENUE GROWTH IN H1 FY2025 OF 4.5% LEADERSHIP EVOLUTION • Total revenue $62.7 Million vs $60.0 Million PCP. Up 4.5%. • New CEO Geoffrey Cockerill started late November 2024. • Normalised EBITDA of $4.6 Million (PCP Normalised EBITDA • New Chief Operating Officer, Chief Technol
Slide 11: Market conditions and diversification
For personal use only Medicinal cannabis market still growing, but Diversifying the business and revenue streams Pressures on health infrastructure driving remains competitive and price sensitive patients online • Vitura’s wholly-owned subsidiary, Burleigh • Acquisitions of Doctors on Demand, Releaf
Slide 12: Operational Overview
OPERATIONAL OVERVIEW For personal use onl
Slide 13: Integrated end-to-end digital health platform
For personal use only Fully integrated end-to-end digital health platform with services at every step of the patient journey: • 24-hour telehealth services through Doctors on Demand. • Acquisition of Releaf assets and Candor Medical adds to digital health patient reach, providing an expanding range
Slide 14: Doctors on Demand
For personal use only • Doctors on Demand (DoD) was acquired by Vitura in October 2023. • Contributed $14.4M revenue in first 8 months (Nov 2023-June 2024), from its nationwide telehealth services. • In H1 FY2025, DoD continued to deliver strong growth. • Monthly consultation numbers increased by 58
Slide 15: Releaf assets and Candor Medical acquisitions
For personal use only • Vitura’s 50% joint venture company - Flora Holdings Pty Ltd - acquired the majority of assets held by Releaf Group Limited in November 2024. • Around 30,000 patients were registered with Releaf’s clinics when the assets were acquired. • Flora has now engaged with the Releaf p
Slide 16: Clinic integration
For personal use only • Vitura’s existing clinics, CDA and Cannadoc, will be migrated to the newly acquired Candor platform. • This will deliver a significant increase in the operations and size of Vitura’s specialised clinic offerings and valuable efficiencies. • The combination of CDA, Cannadoc an
Slide 17: Canview platform progress
For personal use only • Acquisition of Canview technology platform copy completed in late February 2025. • Supports plans for further platform enhancement to better connect patient prescriptions to medication orders. • 185 unique product SKUs added to the Canview platform in H1 FY2025, bringing the
Slide 18: H1 FY2025 Detailed Financials
H1 FY2025 DETAILED FINANCIALS Cc O oO n =) © Cc O ep) — oO ok _ Oo LL
Slide 19: Key Points
For personal use only Key Points • Group operating revenue increased 4.5%, despite a challenging environment. H1 H1 A$M FY2025 FY2024 • Normalised EBITDA and NPAT in H1 FY2025 showed clear improvement on same figures for H2 FY2024, demonstrating growth and continuing momentum. Operating revenue 62.7
Slide 20: Total revenue $62.7M
For personal use only Total revenue $62.7M • Revenue generated in the period up 4.5%. • Consulting and service fees growing strongly. Comprising: • Product sales of $50.0M • Leveraging newly acquired businesses (Releaf and Candor Medical) • Consulting and service fees of $12.7M to continue growth an
Slide 21: Cash flows
For personal use only 31 Dec. 2024 31 Dec. 2023 • During the half-year ended 31 December 2024, cash receipts from $ $ customers (including GST) were $68.2 Million, representing an Cash flows from/(used in) operating activities increase of $5.4 Million (or 9%), on the PCP. Receipts from customers 68,
Slide 22: Financial position
For personal use only 31 Dec. 2024 30 June 2024 • Group cash and cash equivalents decreased by $3.95 Million (or 35%) to $7.39 $ $ Million (2024: $11.35 Million). Cash and cash equivalents 7,396,996 11,347,887 Trade and other receivables 8,837,441 13,736,288 • Main drivers include a $2.5 Million cas
Slide 23: Outlook
For personal use only • Increase total revenue generated in FY2024 by 10%. • Improve EBITDA margin generated in FY2024 by 3%. • Improve OPEX efficiency in FY2025 by 10%.
Slide 24: For personal use only
• • • • • • • For personal use only
Slide 25: Disclaimer applying to this Presentation
Disclaimer applying to this Presentation The following disclaimer applies to this presentation (Presentation) Do are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any Conformation contained in this Presentation. This Presentation h
Slide 26: For personal use only
.. irsonal use only y 7 vitura.com.au WITURA _ VITURA HEALTH LIMITED V info@vitura.com.au 1S0mmaiad °|